A Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder
Brief description of study
This is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy of pimavanserin compared to placebo when given adjunctively to a selective serotonin reuptake inhibitor (SSRI)/serotoninnorepinephrine reuptake inhibitor (SNRI) antidepressant as treatment of patients with Major Depressive Disorder (MDD) who had inadequate response to antidepressant therapy.
Detailed description of study
Participants will be randomized to receive:
• Placebo + antidepressant (SSRI or SNRI)
• Pimavanserin + antidepressant (SSRI or SNRI)
The study duration will be up to 17 weeks.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Depression,Major depression,Depression,MajorDepressiveDisorder,depression
-
Age: Between 18 Years - 65 Years
-
Gender: All
Updated on
04 Jul 2023.
Study ID: 826976